07:00 , Oct 7, 2013 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
07:00 , Aug 27, 2012 |  BC Week In Review  |  Company News

Teva, Mylan, Ranbaxy, Takeda sales and marketing update

The companies launched generic versions of diabetes drugs Actos pioglitazone and ACTOplus met pioglitazone/metformin in the U.S. Ranbaxy and Teva launched authorized generics of Actos, while Mylan and Teva launched authorized generics of ACTOplus met....
08:00 , Jan 3, 2011 |  BC Week In Review  |  Company News

Breckenridge Pharmaceuticals Inc., Synthon Pharmaceuticals Inc., Watson, Aurobindo, Dr. Reddy's, Mylan, Novartis, Ranbaxy, Takeda, Teva, Torrent, Wockhardt endo

Takeda settled patent suits filed against companies that submitted ANDAs for generic versions of diabetes drugs Actos pioglitazone, ACTOplus met pioglitazone/metformin and duetact pioglitazone/glimepiride. Takeda granted Teva rights to an authorized generic version of Actos...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Company News

Takeda sales and marketing update

Takeda's Takeda Pharmaceuticals North America Inc. subsidiary launched ACTOplus met XR extended-release pioglitazone/metformin tablets in the U.S. to treat Type II diabetes. The once-daily fixed-dose combination of a peroxisome proliferation activated receptor (PPAR) gamma agonist...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Metact regulatory update

Japan's Ministry of Health and Welfare approved an NDA from Takeda for Metact pioglitazone/metformin to treat Type II diabetes. The fixed-dose combination of a peroxisome proliferation activated receptor (PPAR) gamma agonist and metformin is already...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

ACTOplus met pioglitazone/metformin: Phase III data

A double-blind, Phase III trial in 600 Type II diabetes patients showed that twice-daily ACTOplus met (15 mg Actos pioglitazone/850 mg metformin) met the primary endpoint of a significant decrease from baseline in HbA1c compared...
07:00 , May 18, 2009 |  BC Week In Review  |  Clinical News

ACTOplus met XR pioglitazone/extended-release metformin regulatory update

FDA approved extended-release ACTOplus met XR to treat Type II diabetes in adults already receiving Actos pioglitazone and metformin or who have inadequate glycemic control on Actos or metformin alone. Once-daily ACTOplus met XR combines...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Clinical News

ACTOplus met regulatory update

The company added a boxed warning to the label for ACTOplus Met to warn that thiazolidinediones, including pioglitazone, cause or exacerbate congestive heart failure in some patients, and that ACTplus Met is not recommended in...
07:00 , Sep 24, 2007 |  BC Week In Review  |  Clinical News

ACTOplus Metpioglitazone/metformin regulatory update

CHMP recommended removing a contraindication from the label of Competact pioglitazone/metformin warning against concurrent administration with insulin in patients with Type II diabetes. Takeda markets the peroxisome proliferation activated receptor (PPAR) gamma agonist and metformin...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Clinical News

Actos pioglitazone regulatory update

Takeda issued a "Dear Healthcare Provider" letter for Actos pioglitazone, Actoplus met (pioglitazone and metformin) and duetact (pioglitazone and glimepiride) to warn of a risk of fracture in female patients. Recent safety data showed more...